UPDATE 1-Roche takes $5.7 mln bid to Illumina shareholders
March 20, 2012
ZURICH, March 20 (Reuters) - - Swiss drug maker Roche on Tuesday took its $5.7 billion bid for Illumina directly to shareholders hoping to persuade them that the U.S. gene decoder faces pressure on... Read More
category
companyNews
UPDATE 1-FDA approves generic Boniva for osteoporosis
March 19, 2012
March 19 (Reuters) - The first generic versions of Roche's bone-strengthening drug Boniva have been approved by the U.S. Food and Drug Administration. Read More
category
companyNews
TABLE-Norway's SWF largest holdings at end-2011
March 16, 2012
OSLO, March 16 (Reuters) - Below are the biggest equity and fixed-income holdings in Norway's $606-billion sovereign wealth fund (SWF), as given in its annual report on Friday. Holdings in billions of... Read More
category
companyNews
Leukemia gene mutations linked to survival odds
March 14, 2012
March 14 (Reuters) - Advances in genetic profiling are paving the way for more precise, and effective, treatment of the aggressive bone marrow cancer known as acute mylogenous leukemia, or AML,... Read More
category
companyNews
NEW YORK, March 14 (Reuters) - Wall Street opened little changed on Wednesday as investors weighed comments from the U.S. Federal Reserve on the economy and banking sector against the recent five-day... Read More
category
companyNews
US STOCKS - Futures edge higher on economic optimism
March 14, 2012
NEW YORK, March 14 (Reuters) - U.S. stock index futures edged higher on Wednesday, putting the benchmark index on track for its sixth straight advance after comments from the U.S. Federal Reserve on... Read More
category
companyNews
March 13 (Reuters) - Swiss drugmaker Roche Holding AG said it received a request for additional information from the Federal Trade Commission (FTC) related to its $5.7 billion hostile cash bid for U.S.... Read More
category
companyNews
Biotech Trends: Analysts Expect Big Growth for Genetic Testing Industry (GHDX, ILMN, LIFE, MYGN)
March 13, 2012
LIPPER: Value, growth duke it out for supremacy
March 12, 2012
NEW YORK, March 12 (Reuters) - It's a debate as old as iconic investor Ben Graham himself: Are you a value investor, attracted to stocks that have been unfairly overlooked and are selling at a bargain?... Read More
category
companyNews
Abcam will pay $170 million to buy Epitomics, a US mAb pharma with a China manufacturing facility; Jiangxi Boya Bio-Pharma completed a $60 million IPO on the ChiNext exchange; 3SBio will form a $20... Read More
from ChinaBio® Today
UPDATE 1-Citi CEO Pandit's 2011 pay soars to $14.9 mln
March 08, 2012
NEW YORK, March 8 (Reuters) - Citigroup Chief Executive Vikram Pandit finally got his payday. The third biggest U.S. bank company paid Pandit $14.86 million in 2011, compared with a salary of $1 and no... Read More
category
companyNews
For Roche, China Is Necessary
March 08, 2012
Roche said its China revenues jumped 35% in 2011, though the company did not release specific figures. China is important to Roche, said CEO Severin Schwan at the company’s annual meeting, in part... Read More
from ChinaBio® Today
PDAC-Africa emerges as new frontier for gold M&A
March 06, 2012
TORONTO, March 6 (Reuters) - At the massive Prospectors and Developers convention, it's not hard to find a table full of mining executives huddled in conversation, their voices muffled by the din of... Read More
category
companyNews
Roche sees alternatives to Illumina if bid fails
March 06, 2012
ZURICH, March 6 (Reuters) - Roche still hopes to succeed in its $5.7 billion hostile cash bid for U.S. gene decoder Illumina, but sees other alternatives if the takeover fails on price, the Swiss... Read More
category
companyNews
Deals of the day -- mergers and acquisitions
February 27, 2012
Feb 27 (Reuters) - The following bids, mergers, acquisitions and disposals involving European, U.S. and Asian companies were reported by 1000 GMT on Monday. Read More
category
companyNews
UPDATE 3-Roche sticks to price in extended Illumina offer
February 27, 2012
category
companyNews
Roche extends Illumina offer until late March
February 27, 2012
ZURICH, Feb 27 (Reuters) - Swiss drugmaker Roche announced on Monday it had extended its offer of $44.50 per share for gene sequencing company Illumina until March 23. Read More
category
companyNews
Roche seen extending Illumina offer at same price
February 24, 2012
category
companyNews
Egyptian firm in fake Avastin scam proves elusive
February 21, 2012
CAIRO, Feb 21 (Reuters) - The trail of counterfeit copies of the multibillion-dollar cancer drug Avastin leads to an address in a crowded Cairo suburb, with no sign of the firm named by international... Read More
category
companyNews
After-Hours Movers 02/16: (SPWR) (AMAT) (CLD) Higher; (RMTR) (PRGN) (QLIK) (MDRX) Lower
February 16, 2012
Rogers Corp. (ROG) Tops Q4 EPS by 14c
February 16, 2012
Trading Radar for 02/16: GM (GM), Baidu.com (BIDU), Altria (MO), Orbitz (OWW), Sunpower (SPWR) Report
February 15, 2012
U.S. stock index futures signal higher Wall St open
February 15, 2012
* U.S. stock index futures pointed to a higher open for equities on Wall Street on Wednesday, with futures for the S&P 500, Dow Jones and Nasdaq 100 rising 0.5 to 0.6 percent. Read More
category
companyNews
PRESS DIGEST - Wall Street Journal - Feb 15
February 15, 2012
Feb 15 (Reuters) - The following were the top stories in The Wall Street Journal on Wednesday. Reuters has not verified these stories and does not vouch for their accuracy. Read More
category
companyNews
PRESS DIGEST - New York Times business news - Feb 15
February 15, 2012
Feb 15 (Reuters) - The following were the top stories on The New York Times business pages on Wednesday. Reuters has not verified these stories and does not vouch for their accuracy. Read More
category
companyNews
Shareholders sue Illumina over Roche bid
February 14, 2012
Feb 14 (Reuters) - A group of Illumina shareholders has filed a putative class action against the life sciences company alleging that its directors adopted a poison pill plan to thwart a takeover by... Read More
category
companyNews
Counterfeits of Roche cancer drug found in US
February 14, 2012
category
companyNews
UPDATE 2-Illumina rejects Roche's bid as inadequate
February 07, 2012
NEW YORK, Feb 7 (Reuters) - Illumina rejected as inadequate on Tuesday a $5.7 billion hostile takeover bid from Roche, saying it undervalues the gene sequencing company. Read More
category
companyNews
UPDATE 1-Roche breast cancer drug gets FDA priority review
February 07, 2012
Feb 7 (Reuters) - U.S. health regulators granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. Read More
category
companyNews
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here